Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...
Monthly Prescribing Reference

High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
Medscape

NICE Recommends Ublituximab for Relapsing MS in Adults

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
Healio

Ublituximab demonstrates sustained benefit for relapsing MS in interim open-label analysis

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...
Seeking Alpha

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...
Healio

Comorbidities do not affect treatment for relapsing MS in Black, Hispanic patients

Please provide your email address to receive an email when new articles are posted on . The most common comorbidity for both subsets of the study population was obesity. Risk for infection-related ...
Monthly Prescribing Reference

Tolebrutinib Under Review for Non-Relapsing Secondary Progressive MS

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Nasdaq

60 Degrees Pharmaceuticals Begins Expanded Access Study for Tafenoquine in Immunosuppressed Patients with Relapsing Babesiosis

60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in an expanded access study (NCT06478641) assessing the effectiveness of tafenoquine in treating patients with persistent ...